Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Enzon Pharmaceuticals ( (ENZN) ) is now available.
On January 30, 2026, Enzon Pharmaceuticals, Inc. entered into a Seventh Amendment to its Section 382 Rights Agreement, further adjusting the final expiration date of shareholder rights designed to protect the company’s tax attributes. This latest change moves the final expiration from the close of business on January 31, 2026, to noon New York City time on March 2, 2026, following a series of prior amendments between 2021 and 2025 that repeatedly reset the termination date of the plan. Management stated that extending the rights plan is in the best interests of the company and its shareholders, signaling a continued focus on preserving the value of its tax assets and maintaining flexibility around potential ownership changes that could affect those benefits, while leaving all other terms of the agreement unchanged.
More about Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc. operates in the biopharmaceutical industry, historically focused on developing and commercializing therapies, including oncology-related products, and managing its remaining assets and tax attributes as it evaluates strategic options for shareholder value.
Average Trading Volume: 81,442
Technical Sentiment Signal: Sell
Current Market Cap: $4.9M
For an in-depth examination of ENZN stock, go to TipRanks’ Overview page.